- Enhance the biopharmaceutical industry in Japan/Asia through the further expansion of currently the US/Europe-focused KBI’s business into Japan/Asia, with the acquisition of cutting-edge U.S. technology and expertise in the development and manufacturing of biopharmaceuticals such as antibodies
- Drive biopharmaceutical drug discovery by establishing a value chain from research, development, and manufacturing, combined with INCJ’s network of Japanese biotechnology companies and small- and medium-sized pharmaceutical companies
Our Portfolio
KBI Biopharma Inc.
Outline | Biopharmaceutical contract analytical/process development/manufacturing services for large pharmaceutical companies and biotechnology companies |
---|---|
Website | |
Industry | Health/medicine |
Commercialization stage | Utilization of overseas management resources |
Provided Support
Authorized Investment | US$50 million (maximum) |
---|---|
Announcement Date | Feb 26, 2015 / Dec 08, 2016 |
Investment Structure |